Emergent BioSolutions Secures ~$54M Contract To Provide CNJ-016 Vaccinia Immune Globulin Intravenous To U. S. Department of Health And Human Services' Administration For Strategic Preparedness And Response For Smallpox Preparedness; Gets New $6.6M Incremental Orders With Undisclosed Global Federal Partner For ACAM2000

Emergent BioSolutions Inc. (NYSE: EBS) has secured a contract worth approximately $54 million to provide CNJ-016 (Vaccinia Immune Globulin Intravenous) to the U.S. Department of Health and Human Services for smallpox preparedness. Additionally, the company received new incremental orders valued at $6.6 million for ACAM2000 (Smallpox Vaccine) from an undisclosed global federal partner, highlighting ongoing efforts in biodefense.